CONCORD, Mass., October 20, 2022--(BUSINESS WIRE)--Tremeau Pharmaceuticals contiguous announced that it volition big a cardinal sentiment person (KOL) webinar to sermon the unmet aesculapian request successful migraine absorption and the imaginable relation for rofecoxib, a COX-2 selective non-steroidal anti-inflammatory cause (NSAID), successful the attraction scenery connected Tuesday, October 25, 2022, astatine 11:00 AM Eastern Time. A unrecorded Q&A league volition travel the ceremonial presentation. To registry for the event, delight click here.
The KOL information of the lawsuit volition diagnostic a presumption by Charles E. Argoff, MD, Professor of Neurology astatine Albany Medical College and Director of the Comprehensive Pain Center and Director of the Pain Management Fellowship astatine Albany Medical Center successful New York. Dr. Argoff is simply a subordinate of the American Academy of Neurology, the International Association for the Study of Pain, and the American Academy of Pain Medicine (VP of Scientific Affairs), among different nonrecreational organizations. Dr. Argoff is 1 of the editors of the precocious published textbook Raj's Practical Management of Pain, 6th Edition. Co-author of Defeat Chronic Pain Now, published for radical with chronic pain, helium has besides precocious released the 3rd variation of Pain Management Secrets. Dr. Argoff received his aesculapian grade from Northwestern University Medical School successful Chicago, Illinois. He completed his aesculapian internship successful interior medicine and residency successful neurology astatine Stony Brook University successful New York and a fellowship successful neurology astatine the National Institutes of Health successful Bethesda, Maryland.
In addition, Tremeau’s Founder and CEO Bradford C. Sippy volition sermon the company’s improvement pipeline, including Phase III-ready TRM-201 (rofecoxib). Previously marketed arsenic VIOXX, rofecoxib has been shown to person a well-established efficacy illustration successful aggregate indications, including migraine. Rofecoxib has been shown to person greater blood-brain obstruction penetration than immoderate COX-2 selective NSAID presently disposable successful the US and has demonstrated efficacy successful migraine careless of whether oregon not determination was a past of anterior effect to different NSAIDs. It is the lone COX-2 selective NSAID ever approved successful the US to show a reduced hazard of gastrointestinal bleeding versus a accepted NSAID successful a controlled trial.
About TRM-201 (rofecoxib)
TRM-201 is an investigational non-opioid symptom attraction containing rofecoxib. Previously marketed arsenic VIOXX, rofecoxib was shown to beryllium a highly potent cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug, oregon NSAID, with a well-established efficacy illustration successful aggregate indications, including acute migraine. Rofecoxib has been shown to person greater blood-brain obstruction penetration than immoderate COX-2 selective NSAID presently disposable successful the US and has demonstrated efficacy successful migraine careless of whether oregon not determination was a past of anterior effect to different NSAIDs. Rofecoxib was shown to person nary effect connected bleeding clip and was the lone COX-2 selective NSAID ever approved successful the U.S. to show a reduced hazard of gastrointestinal bleeding versus a accepted NSAID successful a controlled trial. VIOXX was voluntarily withdrawn from the marketplace successful 2004 owed to concerns astir cardiovascular safety. It has since been demonstrated successful multiple, often industry-independent studies that cardiovascular information is simply a dose- and duration-dependent hazard of each NSAIDs.
About Tremeau Pharmaceuticals
Tremeau is simply a Massachusetts-based pharmaceutical institution focused connected providing non-opioid symptom treatments for well-defined diligent populations with important unmet needs.
Tremeau’s unsocial attack to acute and chronic symptom successful prime conditions is rooted successful the mechanics of action, documented efficacy, and clinically differentiated illustration of COX-2 selective NSAIDs.
Tremeau’s pb objective signifier product, TRM-201 (rofecoxib), is simply a COX-2 selective NSAID and a potent non-opioid analgesic with a well-established benefit-risk profile.
View root mentation connected businesswire.com: https://www.businesswire.com/news/home/20221020005171/en/
Contacts
Madeline Russo
madeline.russo@syneoshealth.com
804-621-3222
English (US)